Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Hikma Pharmaceuticals PLC develops, manufactures, markets, and sells a range of generic, branded, and in-licensed pharmaceutical products. It operates through three segments: Injectables ...

Hikma Pharmaceuticals PLC HIK shares shed 3.16% to £19.02 Friday, on what proved to be an all-around rough trading session ...

The acquisition includes a commercial portfolio and pipeline of differentiated products, a manufacturing facility in ...

Hikma is offering clindamycin in 5% dextrose injection, in 300mg/50ml, 600mg/50ml and 900mg/50ml doses. The product is available in a vial. Clindamycin in 5% dextrose injection is indicated for ...

(Alliance News) - Hikma Pharmaceuticals PLC announced on Tuesday it has completed its acquisition of the US finished dosage form business. Denmark-based Xellia Pharmaceuticals ApS. Xellia's FDF ...

Also Read: Why Is Jazz Pharmaceuticals Stock Trading Lower ... and emphasized that other narcolepsy treatments are available. Hikma’s generic version of Xyrem only reached the market last ...

Saudi Ministry of Health supports December launch event in Riyadh; Event to highlight Saudi Arabia’s ambitious pharma goals, ...

Hikma Pharmaceuticals in the US joined government officials and non-profit leaders today at a naloxone awareness and training event organized and hosted by Rep. Earl L. "Buddy" Carter of Georgia.

The Price to Earnings (P/E) ratio, a key valuation measure, is calculated by dividing the stock's most recent closing price by the sum of the diluted earnings per share from continuing operations ...